EntreMed (ENMD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Winkler who wrote (830)	5/7/1998 2:23:00 PM
From: Michael Greene	Read Replies (5) of 2135

David, In today's WSJ, in the Heard on the Street column, Dr. Folkman is quoted as saying that "his lab has since discovered four other unnamed vessel-blocking agents that may be even more potent than the two being developed by EntreMed. He said no company has the rights to develop these." Is this news to you? I do not remember previous mention of additional and more potent agents since the announcement of Endostatin. As far as the rights to these agents go I was a little surprised that "no company has the rights to develop these" since Entremed's annual report stated that "The company holds the worldwide, exclusive rights to angiogenesis products invented by Dr. Folkman and his team of scientists". Perhaps this is explainable from the following in the 10K -- "The Company obtained an an exclusive option to negotiate an exclusive, worldwide, royalty-bearing license to any technology resulting from the research at Children's Hospital in areas covered by the agreement." Is it your understanding that EntreMed has a right of first refusal on Dr. Folkman's angiogenesis developments? Michael

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next